

INTRODUCING EUROFINS BEACON DISCOVERY

The GPCR Experts



Eurofins Discovery welcomes a new company to its organization, Beacon Discovery. Eurofins Beacon Discovery is an industry leader in GPCR drug discovery offering an integrated approach for challenging GPCR targets. The Team has identified in excess of 30 pre-clinical candidates of which more than 20 programs have moved successfully into clinical development. Key to Eurofins Beacon Discovery's success is the ability to critically evaluate new targets with knowledge acquired from over 20 years of working on this crucial target class.

- Industry leading know-how on all aspects of GPCR biology
- Complete GPCR drug discovery solution utilizing advanced discovery platforms and technologies
- Renowned expertise in prosecuting orphan GPCR targets across therapeutic areas

PARTNERING FOR SUCCESS

Eurofins Beacon Discovery's reputation in the field of GPCR discovery is built on the success of its partnerships with biotech and pharma companies worldwide. Beacon scientists take a flexible approach in all of their collaborations with the purpose of designing high quality compounds by employing seasoned medicinal chemistry supported by state-of-the-art computational tools. This chemistry approach combined with a powerful expertise in assay development, mode of action, and biomarker establishment capabilities for over 20 years makes Eurofins Beacon Discovery the partner of choice for your GPCR programs. Join our community of partners who have trusted Eurofins Beacon Discovery to get the biology right in their relentless endeavor to discover and develop life changing drugs.

Learn more about GPCR Integrated Drug Discovery and ways to collaborate with Eurofins Beacon Discovery at beacondiscovery.com

WORKING WITH EUROFINS BEACON DISCOVERY

Support from Concept to Clinic

INTEGRATED WORKFLOW DESIGNED WITH YOUR UNIQUE PROGRAM IN MIND

Eurofins Beacon Discovery employs an integrated workflow which supports GPCR discovery programs from target validation to providing pre-clinical candidates, with a proven success rate of reaching the clinic. The combination of Eurofins Beacon Discovery's 600,000 compound screening library and expert biology with proficient medicinal chemistry support is a valid approach to addressing GPCR targets and has been particularly effective for orphan GPCR.




Figure 1. Take advantage of Eurofins Beacon Discovery's sophisticated and integrated workflow to fast-track your GPCR drug discovery programs.

For more information on Eurofins Beacon Discovery and how we can support your GPCR discovery programs, please visit beacondiscovery.com